Abstract
Recent advances in research on depression have confirmed that it is common, recurrent and disabling mental disorder. Current medication for the treatment of depression have limited efficacy and delayed onset of therapeutic action. In view of the limitation of the current antidepressant pharmaceuticals, tremendous research efforts are ongoing to search for a pharmacological treatment which may improve antidepressive efficacy, onset of action or even both therapeutic parameters. To address these needs, numerous combination therapies that maintain the benefits associated with selective serotonin reuptake inhibitors (SSRIs) but attempts to improve efficacy or reduce side effects by additional mechanism (5-HT1A, 5-HT2C ) and newer approaches targeting excitatory (glutamate, NMDA,mGluR2, mGluR5) or inhibitory aminoacid system (GABA) or peptidergic system(neurokinin1, corticotrophin releasing factor1, melanin concentrating hormone1) have been identified. The goal of this review is to give a brief overview of the major advances in monoamine based treatment strategies and the new emerging approaches in the treatment of depression.
Keywords: Depression, SSRIs, GABA, monoamine, glutamate, serotonin
Current Pharmaceutical Design
Title: Antidepressants: Current Strategies and Future Opportunities
Volume: 16 Issue: 38
Author(s): Archana Uppal, Anita Singh, Prashant Gahtori, Surajit Kumar Ghosh and Mohammad Zaki Ahmad
Affiliation:
Keywords: Depression, SSRIs, GABA, monoamine, glutamate, serotonin
Abstract: Recent advances in research on depression have confirmed that it is common, recurrent and disabling mental disorder. Current medication for the treatment of depression have limited efficacy and delayed onset of therapeutic action. In view of the limitation of the current antidepressant pharmaceuticals, tremendous research efforts are ongoing to search for a pharmacological treatment which may improve antidepressive efficacy, onset of action or even both therapeutic parameters. To address these needs, numerous combination therapies that maintain the benefits associated with selective serotonin reuptake inhibitors (SSRIs) but attempts to improve efficacy or reduce side effects by additional mechanism (5-HT1A, 5-HT2C ) and newer approaches targeting excitatory (glutamate, NMDA,mGluR2, mGluR5) or inhibitory aminoacid system (GABA) or peptidergic system(neurokinin1, corticotrophin releasing factor1, melanin concentrating hormone1) have been identified. The goal of this review is to give a brief overview of the major advances in monoamine based treatment strategies and the new emerging approaches in the treatment of depression.
Export Options
About this article
Cite this article as:
Uppal Archana, Singh Anita, Gahtori Prashant, Kumar Ghosh Surajit and Zaki Ahmad Mohammad, Antidepressants: Current Strategies and Future Opportunities, Current Pharmaceutical Design 2010; 16 (38) . https://dx.doi.org/10.2174/138161210794519110
DOI https://dx.doi.org/10.2174/138161210794519110 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Editorial (Thematic Issue: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics)
Current Vascular Pharmacology A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Synthesis and Antithrombotic Activity Study of Some New Thienopyridine Derivatives
Letters in Organic Chemistry Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Current Topics in Medicinal Chemistry The Atherogenic Dyslipidemia of Metabolic Syndrome- Are there New Effective Therapeutic Options Beyond Statins?
Current Drug Therapy Diabetic Cognitive Dysfunction: From Bench to Clinic
Current Medicinal Chemistry Vasoprotective Actions of the Atrial Natriuretic Peptide
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress
Current Topics in Medicinal Chemistry Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Analysis of Heart Rate Variability and Implication of Different Factors on Heart Rate Variability
Current Cardiology Reviews Preface: (Commentary on the Special Issue on the Impact of Myogenic Tone in Health and Disease)
Current Vascular Pharmacology